Brokerages have assigned an average recommendation of “Buy” to Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has received an average “Buy” recommendation from the nine brokerages covering the company, according to MarketBeat.

READ: OAS to Step in as Mediator in Guatemala’s Power Transition Crisis

Rocket Pharmaceuticals

Nine analysts have given the stock a buy rating, with the average 12-month price target among these analysts standing at $52.57 based on their coverage over the past year.

Several research analysts have recently provided their insights on Rocket  Needham & Company LLC reiterated a “buy” rating and set a $53.00 price target for  Pharmaceuticals in a research note on Tuesday, November 7th.

Cantor Fitzgerald initiated coverage on Rocket Pharmaceuticals on Tuesday, October 24th, giving the stock an “overweight” rating and a $65.00 price target. Lifesci Capital reaffirmed an “outperform” rating on  Pharmaceuticals on Tuesday, December 26th.

Additionally, StockNews.com upgraded  Pharmaceuticals to a “sell” rating in a research report on Tuesday, October 24th